Item Type: | Article |
---|---|
Title: | CTGF/CCN2 has a possible detrimental role in the inflammation and the remyelination failure in the early stages of multiple sclerosis |
Creators Name: | Fuchs, L. and Mausner-Fainberg, K. and Luban, A. and Asseyer, S.E. and Golan, M. and Benhamou, M. and Volovitz, I. and Regev, K. and Vigiser, I. and Piura, Y. and Kolb, H. and Paul, F. and Karni, A. |
Abstract: | Connective tissue growth factor (CTGF/CCN2) is a proinflammatory and an oligodendrocyte-differentiating blocking agent. It is found in MS lesions, which raises the possibility of involvement in MS pathogenesis. We found that its CSF and serum levels were higher in RR-MS patients than in controls and for serum compared to PP and SP-MS. Immune cells of both RR-MS and controls secreted CTGF/CCN2, which was enhanced by CD3/CD28 stimulation or by LPS. Anti-CTGF treatment of mice with experimental autoimmune encephalitis ameliorated its clinical severity. CTGF/CCN2 may play a role in the immune pathogenesis of MS and in remyelination failure in early stages of MS. |
Keywords: | Connective Tissue Growth Factor, Inflammation, Multiple Sclerosis, Remyelination, Animals, Mice |
Source: | Journal of Neuroimmunology |
ISSN: | 0165-5728 |
Publisher: | Elsevier |
Volume: | 371 |
Page Range: | 577936 |
Date: | 15 October 2022 |
Official Publication: | https://doi.org/10.1016/j.jneuroim.2022.577936 |
PubMed: | View item in PubMed |
Repository Staff Only: item control page